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Abstract: The pharmacological efficacy of various monotherapy, single pill, and combination 
therapies of the angiotensin II receptor blocker valsartan have been established, mainly through 
randomized controlled trials that used similar methodological and statistical platforms and 
thus enabled synthesis of evidence. The real world effectiveness of valsartan has been studied 
extensively, but the relative lack of scientific and technical congruence of these studies render 
synthesis virtually impossible. To date, all have focused on blood pressure outcomes, despite 
evidence-based calls to grade antihypertensive treatment to patients’ total cardiovascular risk. 
We review a T3 translational research program of seven studies involving valsartan monotherapy 
as well as single and separate pill combinations, and the determinants and effect on blood pres-
sure and total cardiovascular risk outcomes. All seven studies examined not only the impact 
of valsartan-based regimens on blood pressure values and control, but also, within a statistical 
hierarchical approach, the physician- and patient-related determinants of these blood pressure 
outcomes. Two studies also investigated the determinants and outcomes of valsartan-based 
treatment on total cardiovascular risk – among the first studies to use this risk coefficient as an 
outcome rather than only a determinant. These seven studies included a total of 19,533 patients, 
contributed by 3434 physician-investigators in Belgium – a country particularly well-suited for 
observational effectiveness studies because of demographics and epidemiology. Each study 
used the same methodological and statistical platform. We summarize the impact of various 
valsartan regimens on such outcomes as blood pressure values and control, change in total 
cardiovascular risk, and reduction in risk by at least one category. We also review the results 
of statistical multilevel and logistic modeling of physician- and patient-related determinants 
on these outcomes, including the proportion of variance attributable to a physician class effect 
before patients enter the equation. In its different formulations, valsartan has major real-world 
benefits in lowering blood pressure and total cardiovascular risk within a 90-day period. It is 
essential to understand the physician- and patient-related determinants of blood pressure and 
total cardiovascular risk outcomes associated with valsartan treatment. Antihypertensive research 
should expand its historical focus on lowering blood pressure with an emphasis on lowering 
total cardiovascular research.
Keywords: valsartan, angiotensin II receptor blocker, hypertension, total cardiovascular risk, 
effectiveness, pharmaco-epidemiology
Introduction
Valsartan is an antihypertensive agent of the class of angiotension II receptor 
  blockers (ARB). These agents block the angiotensin II type 1 (AT1) receptor through Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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all   pathways, not just the renin-angiotensin-aldosterone 
  pathway inhibited by angiotensin-converting enzyme (ACE) 
  inhibitors. Blocking the AT1 receptor mediates the blood 
pressure (BP) elevating effects of angiotensin, including 
vasoconstriction, release of aldosterone and antidiuretic 
hormone, sympathetic activation, and constriction of the 
efferent glomerular arterioles. Further, by not blocking the 
angiotensin II type 2 (AT2) receptor, the beneficial effects 
of stimulation of the AT2 receptor are maintained, including 
vasodilation, tissue repair, and cell growth inhibition.1
Several articles offer excellent reviews of randomized 
controlled trials (RCTs) on the efficacy of valsartan.2–5 
The BP-lowering effect of valsartan has been documented 
across patient populations, including children, the elderly, 
women; patients at high risk for cardiovascular disease, with 
diabetes, and with chronic kidney disease; and across racial 
and ethnic groups. In addition to its antihypertensive effect, 
valsartan has also been shown to have a cardioprotective 
effect.2 Treatment with valsartan reduces cardiovascular 
morbidity and mortality following myocardial infarct (MI),2 
in patients with heart failure,2,3 and in patients with coronary 
artery disease;2 it also lowers the incidence of cerebrovascular 
accidents.2 Valsartan shares with other ARBs the ability to 
reduce circulating levels of high-sensitivity C-reactive pro-
tein and oxidized low-density lipoprotein, both biomarkers 
of endothelial dysfunction and cardiovascular risk.2 Valsartan 
has a renoprotective effect in patients with diabetes and/or 
chronic kidney disease as documented by reduced urinary 
albumin and protein excretion.2 Valsartan protects metabolic 
function in high risk hypertensive patients, including those 
with impaired glucose tolerance, diabetes, metabolic syn-
drome, and obesity.2 Moreover, valsartan is safe and well 
tolerated both in mono- and combination therapy and in a 
broad range of hypertensive patients.6
Focus and rationale of review
In this article, we build on the extensive literature on the effi-
cacy of valsartan. We do so, neither by providing yet another 
review of efficacy results nor by trying to provide the first 
review of the even greater number of observational studies 
on the effectiveness of valsartan in routine clinical practice. 
An initial review of the body of observational studies shows 
great variability in the scope and the quality of objectives, 
methodology, analysis, and results;7 the divergent findings 
are unlikely to be representative of valsartan’s effectiveness 
in the daily clinical setting.
Instead, we have chosen to review a novel ‘T3’ 
transla    tional (practice-based) research program8 on the 
  effectiveness of valsartan in the real-world setting. 
This program involves seven studies, conducted since 2004, 
on various formulations of valsartan on a total of 19,533 
patients contributed by 7043 physician investigators in 
Belgium – a country particularly suited for observational 
effectiveness studies because of the logistical advantages 
of a small but densely populated country with two major 
cultures and languages, as well as urban and rural areas. 
Our research program employs an integrated framework 
for observational effectiveness issues in which the 
(conventional) question of whether valsartan works in 
routine clinical practice is complemented by several addi-
tional questions to gain a comprehensive understanding of 
the clinical dynamics of valsartan-based regimens in the 
management of hypertension.
Further, our research program was among the first in 
the health sciences to apply methodological and statisti-
cal techniques from the social sciences to investigate the 
extent to which the outcomes of treatment with valsartan 
are attributable to physician-related factors before any 
patient-related factors enter the equation. Patients seen 
by the same clinician are exposed to his/her hypertension 
knowledge, experience, and practice patterns. Technically, 
this violates the assumption of statistical independence of 
observations. Prior studies have not accounted statistically 
for the potential class effect of several patients being treated 
by the same   physician-investigator, when in fact there is evi-
dence of potential physician determinants. Therefore, both 
patient- and physician-related factors must be examined to 
better understand the variability in BP outcomes in daily 
clinical practice and any differences in RCT efficacy versus 
  ‘real-world’ effectiveness.
A final novel feature of our research program, imple-
mented in two recent studies, is the use of total cardiovascular 
risk (TCVR) as an outcome indicator of antihypertensive 
treatment with valsartan. The 2007 European Society of 
Cardiology-European Society of Hypertension (ESC-ESH) 
Guidelines and the 2009 ESH guideline reappraisal recom-
mend that TCVR be assessed systematically in all patients 
with arterial hypertension and that the intensity of antihyper-
tensive management be graded as a function of TCVR.9,10 This 
assessment can be done on the basis of the SCORE models 
that estimate patients’ 10-year risk of fatal CV disease for 
high and low risk European countries.11 Typically, studies 
use TCVR (or elements thereof) as a determinant or covari-
ate of BP outcomes when, arguably, TCVR can be used as 
an outcome variable of the effectiveness of antihypertensive 
treatment.12,13Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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From efficacy to effectiveness
Efficacy refers to how a treatment works in ideal circum-
stances, when provided to selected patients by providers 
most skilled at providing it.14 In contrast, effectiveness 
refers to how a treatment works under ordinary and variable 
  conditions, prescribed by licensed clinicians with varying 
degrees of expertise and practicing across the spectrum of 
healthcare settings, to treat a heterogeneity of patients.14,15
In order to secure the purest possible efficacy signal, ran-
domized controlled trials tend to be selective in the patients 
recruited (‘perfectly ill’) and the investigators and centers 
participating in the trials (renowned and trusted for their sci-
entific qualities). Treatment is defined narrowly by protocol 
and offers little latitude for deviation.   Clinician-investigators 
are carefully trained in the identification and treatment of 
patients they enroll in the trial. Patients are monitored closely 
during treatment periods that tend to be short. Treatment is 
free to patients.
All this is both appropriate and essential for detecting 
an efficacy signal that demonstrates, as unambiguously 
as possible, the pharmacotherapeutic benefit of an agent 
under conditions of optimal control of potential (known 
and unknown) confounders. However, and certainly for 
treatments of chronic illnesses such as hypertension, RCT 
conditions are not representative of the clinical context in 
which these agents may be used after they have received 
marketing approval. In fact, RCTs for drug registration 
purposes bear poor resemblance to the real-world context 
of daily clinical practice. Patients are of different ages, with 
varying comorbidities, from across the socio-economic 
spectrum, and with compromising personal and family medi-
cal histories. They are unlikely to receive the guidance and 
monitoring given to subjects in RCTs. The cost of treatment 
is partially theirs. Clinicians, ranging from novice to expert, 
received their clinical training from institutions and facilities 
across the quality spectrum, and may have performed above 
or below the median of their education and training cohorts. 
Few facilities will match the scientific credentials of those 
used in the registration trials.
It is not surprising, then, that the real-world effectiveness 
of antihypertensive agents in reducing BP and achieving 
guideline-recommended targets16–18 may differ from the 
efficacy seen in RCTs.19 BP targets may not be reached,20–23 
thus increasing patients’ risk for target organ damage and 
cardiovascular and renal disease.20,24,25 BP outcomes have 
been linked to patient-related factors, such as sociodemo-
graphics, heritability, history, comorbid conditions, lifestyle, 
knowledge about disease and treatment, and medication 
adherence.26,27 The observed variation in physicians’ knowl-
edge about antihypertensive therapy28,29 has not been linked 
directly to BP outcomes, though it is known that older physi-
cians possess less factual knowledge and are less likely to 
adhere to the standards of care when treating hypertension.30 
There also is evidence of a relationship between physician 
practice patterns and BP outcomes.20,27,31,32
Integrated framework for  
observational effectiveness studies
RCTs are the indicated method for determining the efficacy 
of pharmacological agents. However, by necessity RCTs are 
constrained in terms of patients and clinicians included, and 
treatments must be limited to the agent under investigation so 
that unconfounded inferences about an agent’s efficacy can be 
drawn. Observational studies are needed to examine the effec-
tiveness of drugs previously documented to be   efficacious. 
Most observational studies focus narrowly on evaluating 
a treatment’s effectiveness under ‘real-world’ conditions, 
leaving key questions unanswered. The question of ‘whether 
the treatment works?’, while critical, does not address the 
equally important questions of ‘when does the treatment 
work, and when not?’, ‘in whom does the treatment work, 
and in whom not?’, ‘why does the treatment work in some 
patients but not in others?’, ‘why does the treatment work 
with some clinicians but not with others?’, and ‘why is the 
treatment tolerated by some patients but not by others?’
We have developed an integrated framework for obser-
vational studies, which has become a de facto quality model 
to assure clinical relevance, scientific value, and technical 
merit. Figure 1 presents a flowchart of the framework used 
in our research program. Driven by a possible efficacy-
effectiveness gap in ARB treatment – despite the availability 
of evidence-based practice guidelines for the management of 
hypertension – the framework includes four scientific goals 
operationalized into seven research steps.
The first goal is to determine the variability in BP values, 
BP control, and the residual TCVR after treatment with a 
valsartan-based regimen. Consequently, step 1 evaluates, on 
the basis of observed BP values, whether the hypertension 
has been alleviated and whether BP is now within control 
range. More recently, step 1 also evaluates the extent to which 
TCVR has been reduced as a function of lowered BP.
The second goal explores the determinants of observed 
blood pressure reduction at both the physician- and the 
patient-level. At the physician-level, we evaluate their knowl-
edge of hypertension management, in particular as described 
in evidence-based practice guidelines. We examine the extent Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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to which they practice relative to these guidelines (step 2). 
We also collect demographic and professional data.
At the patient level, we assess whether patients adhered 
to their prescribed regimen (step 3). Instead of attempting to 
quantify adherence with ‘pin-point’ accuracy, we advocate 
the use of brief measures that can be integrated easily into 
routine clinical practice. These measures may not provide the 
‘true’ level of a patient’s adherence, but we do not believe 
this is necessary. Clinicians do not have the time for extensive 
adherence assessment. Short and easy methods that give them 
an impression as to whether treatment adherence is a problem 
in a given patient have been shown to be highly predictive of 
the risk for poor treatment response and uncontrolled BP.33 
We also collect data related to demographics, clinical status, 
and knowledge.
Step 4 aims to develop a heuristic profile of patient vul-
nerability to poor treatment outcomes. Deterministic algo-
rithms to determine cardiovascular outcomes are available 
(eg, SCORE,11 Framingham34) but are seldom used in primary 
care. Reasons include the time requirements and the poor fit 
into the clinical flow of primary care encounters. Clinicians 
tend to view deterministic models as prescriptive and discount-
ing their clinical expertise in evaluating patients and assessing 
risk. Similar to adherence assessment, clinicians prefer clini-
cally intuitive guidance for identifying patients who may be 
less likely to achieve good treatment outcomes.35
Driver 1
potential efficacy–effectiveness gap 
Driver 2
evidence-based practice guidelines 
Goal 1
determination of variability in
blood pressure values and control, and
TCVR  
Step 1
examine effectiveness of antihypertensive
treatment 
– BP values 
– BP control 
– TCVR
Goal 2
analysis of determinants: 
physician-level 
patient-level 
Step 2
examine physician knowledge and practice
patterns regarding hypertension management
Step 3
assess patient adherence to antihypertensive treatment  
Step 4
conduct patient vulnerability profiling
Goal 3
modeling of
BP values and control, and TCVR 
Step 5
multilevel/hierarchical linear modeling of
blood pressure values
Step 6 
logistic regression modeling of responders vs 
nonresponders
Goal 4
pharmacovigilance 
Step 7 
safety and tolerability assessment 
Figure 1 integrated framework for observational effectiveness studies; the focus on total cardiovascular risk was added in 2007.
Abbreviations: BP, blood pressure; TCVR, total cardiovascular risk.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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The third goal is to model BP outcomes and changes in 
TCVR. This is done using hierarchical linear (step 5) and 
logistic regression methods (step 6). Hierarchical refers to 
statistical methods in which the class effect on outcomes 
is estimated before actual outcomes are calculated; in our 
research program, the effect of the class of physician as each 
of them contributed several patients to a study and the ensu-
ing loss of independence of observation. In the process, the 
proportion of variance in BP outcomes associated attributable 
to the treating physician is estimated. In step 6, logistic regres-
sion methods are applied to identify independent predictors 
of why some patients do not respond to antihypertensive 
treatment with valsartan.
The final goal concerns continued pharmaco-vigilance. 
Observational studies tend to have larger patient samples 
than RCTs. This adds statistical power to the ability to detect 
safety signals that may not have been detected in prior RCTs. 
Thus observational effectiveness, combined with other post-
approval activities, offer a critical complement to RCTs to 
detect low-frequency adverse events with a statistically low 
likelihood of being detected in efficacy trials.
Review of studies
The research program comprises seven studies on various 
valsartan regimens conducted between 2004 and 2009: 
PREVIEW,19 IMPROVE,36 ADVANCE,37 INSIST,38 
eNOVA,39 BSCORE,40 and EXCELLENT.41 Tables 1 and 2 
summarize the studies in terms of year of initiation, evalu-
able samples, and key patient demographics (Table 1) and 
valsartan formulations included (Table 2). Studies were 
initiated between 2004 and 2008, with the last one (EXCEL-
LENT) completed in 2009. Over the course of the program, 
all approved monotherapy and (single-pill) combination 
formulations were studied, with the exception of valsartan 
320 mg. A total of 19,533 evaluable patients were contributed 
by 3434 physician investigators. Five studies included well 
over 3000 patients each. Mean (±SD) age was consistent 
across studies, and the weighted average was 63.6 years. 
There were minor shifts in gender distribution across studies, 
but on average gender was equally distributed. On average, 
slightly less than a quarter of patients were diabetic.
Core objectives
Consistent with Figure 1, the core objectives across the seven 
studies were to:
1.  Assess systolic (SBP) and diastolic (DBP) blood pressure 
and BP control at 90 days in patients receiving a valsartan 
regimen as second-line treatment because first-line treat-
ment failed or was not tolerated;
2.  Determine the percentage of variance in BP values at 
90 days attributable to a physician class effect;
3.  Examine the hierarchical (patients ‘nested’ under physi-
cians) determinants of BP values at 90 days; and
4.  Identify independent predictors of non-response to 
valsartan-centric treatment.
In addition, the BSCORE and EXCELLENT studies 
also aimed to:
1.  Assess residual TCVR at 90 days, as well as the propor-
tion of patients who achieved a reduction in TCVR of at 
least one category;
2.  Determine the percentage of variance in residual TCVR 
at 90 days attributable to a physician class effect;
3.  Examine the hierarchical determinants of residual TCVR 
at 90 days; and
4.  Identify independent predictors of achieving an improve-
ment in TCVR of at least one category.
Core methodology
Design
All studies included a baseline assessment at the time that 
treatment with valsartan was initiated, and a follow-up assess-
ment approximately 90 days later. The decision to treat with 
Table 1 Key characteristics of studies and samples
Study Year initiated Evaluable samples Patients
Patients Physicians Age (M ± SD) % male % diabetic
PReView 2004 3,194 504 63.4 ± 11.9 47.7 20.4
iMPROVe 2004 3,950 684 63.2 ± 12.3 48.7 19.2
ADVANCe 2005 3,599 602 63.6 ± 12.0 49.4 22.6
iNSiST 2006 1,014 308 63.6 ± 12.0 48.5 32.3
eNOVA 2006 733 284 64.0 ± 11.4 49.0 40.2
BSCORe 2008 3,497 354 63.8 ± 12.0 52.3 23.6
eXCeLLeNT 2008 3,546 698 63.8 ± 11.7 53.9 27.0
weighted avg 63.6 ± 12.0 50.3 23.7
19,533 3,434      Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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valsartan was made by the prescribing physician based on 
his/her best clinical judgment. Being an observational study, 
there were no required tests and all data collected were as 
available from routine clinical practice.
All studies complied with the Declaration of Helsinki. 
Approvals were obtained from appropriate ethical com-
mittees and conform to Belgian legislation and regulations 
and European Union directives regarding the use of human 
subjects. All subjects provided informed consent.
Sampling
Eligible for participation in any of the studies were male and 
female patients whose treating physician decided indepen-
dently and per best clinical judgment to prescribe valsartan 
as second-line mono- or polytherapy, including single-pill 
combinations with hydrochlorothiazide (HCTZ) or amlo-
dipine (Table 2). Patients had to be hypertensive, defined as 
DBP $ 90 mmHg ($80 mmHg for diabetic patients) and/
or SBP $ 140 mmHg ($130 mmHg for diabetic patients). 
Patients with controlled SBP and/or DBP at baseline were 
eligible if the conversion to a valsartan regimen occurred 
because prior-line treatment was not tolerated. Patients with 
sensitivities to any ARBs, thiazides, or calcium channel 
blockers were excluded; as were patients on any investi-
gational drug in the 30 days before enrolment, and patients 
prescribed other ARBs during the study period.
Variables and measurements
The studies included only patient data collected routinely in 
clinical practice. The core data model was developed on the 
basis of literature review and clinical experience. Though 
there were occasional minor variations across the seven stud-
ies in terms of data elements included, essentially all studies 
collected conceptually and/or operationally the same data. All 
data models are available from the corresponding author.
Core data model
Physician questionnaire:  practice type, location/setting, 
patient mix; demographics; sources of information and 
knowledge related to hypertension; self-reported hyperten-
sion management practices; prescription patterns; manage-
ment of side effects; SBP/DBP thresholds for treatment 
initiation and intensification; perceptions of patient adher-
ence; and knowledge of practice guidelines.
Patient baseline data:  demographics; anthropometrics; 
hypertension and CV history; comorbidities; lifestyle; 
prior antihypertensive medications; SBP and DBP; 
physician-reported TCVR (BSCORE and EXCELLENT 
studies only); clinical status; starting doses; all con-
comitant   anti-hypertensive and other relevant medications 
  (prescribed as per physicians’ clinical judgment); self-
reported and physician-rated (0–100) visual analog scale 
adherence within the past 4 weeks; and adherence and 
non-adherence behaviors.
Patient follow-up data (90 days):  SBP and DBP; residual 
physician-reported TCVR (BSCORE and EXCELLENT stud-
ies only); clinical status; changes in dosing since previous visit; 
concomitant medication(s) taken or changed since previous 
visit (prescribed as per physicians’ clinical judgment); self-
reported and physician-rated adherence within the past 4 weeks 
(0–100 visual analog scale with higher values indicating better 
adherence); and adherence and non-adherence behaviors.
Blood pressure:  BP was measured three times at 1- to 
2-minute intervals, in a sitting position after 5 minutes of 
rest. The mean was recorded as the mean sitting systolic 
(MSSBP; hereafter SBP) and diastolic blood pressure 
(MSDBP; hereafter DBP). BP control was defined per the 
2007 ESH-ESC guidelines prevailing at the time of the 
study: SBP , 140 mmHg and/or DB , 90 mmHg, except 
for patients with diabetes mellitus and/or high or very 
high TCVR, in which case targets were ,130/80 mmHg.9 
Table 2 Valsartan formulations included in studies
  80 mg 160 mg 80 mg/12.5 mg  
HCTZ
160 mg/12.5 mg  
HCTZ
160 mg/25 mg  
HCTZ
5 mg  
amlodipine/ 
80 mg
5 mg  
amlodipine/ 
160 mg
10 mg  
amlodipine/ 
160 mg
PReView √ √ √  
iMPROVe √ √ √ √ √  
ADVANCe √ √ √ √ √  
iNSiST √  
eNOVA √ √ √ √  
BSCORe √ √ √ √ √  
eXCeLLeNT           √ √ √
Abbreviation: HCTZ, hydrochlorothiazide.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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The recent 2009 reappraisal10 advocates , 140/90 mmHg 
targets for all populations, including diabetics, but as the 
studies were conducted under the ESH-ESC 2007 guidelines, 
we used the lower BP targets for diabetic patients or patients 
with high or very high CV risk in the analysis.
TCVR (BSCORE and EXCELLENT):  TCVR was reported 
by physicians using the SCORE cross-classification of BP 
by risk factors (eg, smoking, dyslipidemia), metabolic syn-
drome, diabetes, and established CV disease (MI, coronary 
artery disease, heart failure, cerebrovascular conditions, 
peripheral arterial disease) or renal disease (defined as serum 
creatinine . 1.5 mg/dL).42 Possible classifications included: 
average risk – low added risk – moderate added risk – high 
added risk – very high added risk. We computed ‘change in 
TCVR’ by subtracting baseline TCVR from follow-up TCVR, 
yielding possible scores from -4 (greatest improvement in 
TCVR) to +4 (greatest worsening of TCVR). We also clas-
sified patients dichotomously as showing or not showing 
a reduction in TCVR by at least one category at 90 days. 
Patients with established CV or renal disease or patients at 
baseline in the average risk category were not included in 
these latter two calculations as they could not improve in the 
TCVR classification.
Specialized statistical analyses
In addition to general summary statistics, each study included 
advanced modeling techniques to identify determinants of 
BP values, TCVR change scores, BP control, and achieving 
a TCVR reduction of at least one category.
Multilevel or hierarchical linear modeling
Each participating physician recruited several patients, 
therefore patients could not be considered independent but 
instead ‘nested’ under their treating physician. We assumed 
that the nj patients recruited by the jth physician might 
share some proportion of variance in BP values and TCVR 
change attributable to their common physician, possibly 
affecting both variables prior to any patient-specific vari-
ables. We applied unconditional and conditional two-level 
hierarchical linear modeling.43,44 Unconditional modeling 
quantified the variability in patient outcomes attributable 
to a physician class effect (intraclass correlation coefficient 
[ICC]). In the conditional models BP and TCVR were 
first examined in light of physician-level variables. The 
coefficients thus derived were used subsequently in the 
estimation of patient determinants of the BP and TCVR 
effectiveness outcomes.
Hierarchical logistic regression45
This was used to model patient- and physician-level deter-
minants of uncontrolled BP at 90 days; and, in the BSCORE 
and EXCELLENT studies, to identify independent predictors 
of improvement in TCVR.
We have presented summary statistics from random 
effects meta-analyses (Z statistic, Hedges g, P value) to 
estimate effects of BP reduction, taking into account between 
and within study differences, and correlation between 
pre- and post BP values. We have included match-paired 
statistics (McNemar’s and Liddell’s tests) to present the 
statistical significance of changes in BP control compared 
with baseline. We have presented McNemar-Bowker’s test 
to help quantify the improvements in TCVR (improvement 
in matched distributions). With respect to ICCs, we present 
statistics from random effects meta-analyses across studies 
(Z statistic, P value) for SBP and DBP, and χ2 for each study 
with TCVR (test against the null ICC of 0.00).
Results
In this section, we review the aggregate findings across the 
various studies for the effectiveness outcomes: BP values 
and control (Table 3); as well as TCVR for the BSCORE and 
EXCELLENT studies (Table 4); the proportion of variance 
in these effectiveness outcomes that is accounted for by a 
physician class effect (Table 5); the multilevel modeling of 
SBP (Table 6), DBP (Table 7), and TCVR (Table 8); logistic 
modeling of uncontrolled SBP (Table 9), DBP (Table 10), 
combined SBP/DBP (Table 11); and achieving a reduction 
in TCVR of at least one category (Table 12).
effectiveness outcomes
Blood pressure
SBP and DBP values at baseline and after 90 days of valsar-
tan-centric treatment were similar across the seven studies 
(Table 3). Using weighted averages, SBP decreased from a 
mean (±SD) of 155.9 ± 15.4 mmHg to 137.5 ± 11.8 mmHg, 
while DBP decreased from 91.5 ± 9.6 mmHg to 82.0 ± 7.5. 
On the aggregate, then, valsartan regimens were associated 
with absolute reductions in mean SBP of -18.4 mmHg 
(Z = -27.573; Hedges g = 1.225, both P , 0.0001) and mean 
DBP of -9.5 mmHg (Z = -43.768; Hedges g = 1.173, both 
P , 0.0001) compared with baseline values.
On average, 38.2% had controlled SBP, 58.2% con-
trolled DBP, and 32.0% controlled SBP and DBP combined 
at 90 days (Table 2). Although BP control rates varied 
across our studies, there were significant improvements Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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in   proportions of patients with controlled BP compared 
with baseline levels of control (all matched-paired 
P , 0.001).
TCVR
On average, across the BSCORE and EXCELLENT stud-
ies, patients’ TCVR classification decreased by -0.74 ± 0.95 
category over 90 days of antihypertensive treatment (Table 4). 
At 90 days, about 60% of patients had a residual TCVR that 
was at least 1 category lower than at baseline. More telling, 
perhaps, are the observed shifts in risk categories from base-
line to follow-up. As shown in Figure 2, whereas at baseline 
45.9% of patients were classified as having high added risk 
or very high added risk, this proportion declined to 25.6% 
just 90 days later. Compared with baseline, improvements in 
TCVR were significant in both BSCORE and EXCELLENT 
(both McNemar–Bowker χ2 . 1000; P , 0.0001). The modal 
subcohort of 42.0% with moderate added risk at baseline 
was reduced to 26.6% at follow-up, when low added risk 
became the modal subcohort (34.4%). At 90 days, almost 
half of patients (47.7%) qualified for the average risk and 
low added risk categories.
Attribution of variance to physician  
class effect
On average across the seven valsartan studies, 22% of the 
variance in SBP (Z = 22.954; P , 0.0001) and 24% of the 
variance in DBP (Z = 22.619; P , 0.0001) at 90 days was 
attributable to a physician class effect. The average variance 
in residual TCVR accounted for by a physician class effect 
was 15% (BSCORE χ2 = 87.48; P , 0.0001: EXCELLENT 
χ2 = 79.20; P , 0.0001). Thus, anywhere from about one 
fifth to one quarter of patients’ BP values after 90 days of 
valsartan-centric treatment were determined by the treating 
physician – and this before any patient variables entered 
the equation. Similarly, about one seventh of patients’ 
change in cardiovascular risk was a function of the treating 
physician.
Multilevel modeling of blood pressure  
values and TCVR
Tables 6 through 8 summarize the results of the multilevel 
modeling of SBP, DBP, and change in TCVR after 90 days 
of treatment with valsartan-centric antihypertensive regimens 
in each of the seven studies. Following the observed model 
intercept, the top panel lists patient- and the bottom panel 
physician-related variables that were retained.
Table 3 Blood pressure values and blood pressure control rates 
at baseline and 90 days
Systolic Blood pressure  
(mmHg)
Controlled blood  
pressure
Baseline 90 days Baseline 90 days
M ± SD M ± SD % %
PReView 154.4 ± 15.5 139.0 ± 12.0 9.0 38.6
iMPROVe 157.0 ± 16.1 138.7 ± 12.3 6.6 40.4
ADVANCe 155.7 ± 15.3 137.8 ± 11.3 6.6 42.3
iNSiST 158.5 ± 17.2 139.3 ± 13.7 5.6 34.9
eNOVA 156.6 ± 14.3 138.0 ± 11.3 4.5 38.9
BSCORe 154.7 ± 15.3 135.3 ± 11.5 4.6 36.9
eXCeLLeNT 156.3 ± 14.6 136.2 ± 11.3 2.7 33.3
weighted  
average
155.9 ± 15.4 137.5 ± 11.8 5.8 38.2
Diastolic        
PReView 91.3 ± 9.2 82.6 ± 7.4 25.5 65.5
iMPROVe 91.6 ± 9.6 81.9 ± 7.5 23.5 66.9
ADVANCe 91.9 ± 9.5 82.6 ± 7.4 23.0 64.3
iNSiST 93.1 ± 10.3 82.5 ± 8.1 18.8 55.8
eNOVA 93.0 ± 9.2 82.7 ± 7.4 15.8 59.9
BSCORe 90.7 ± 9.8 80.7 ± 7.7 16.5 48.8
eXCeLLeNT 91.4 ± 9.7 81.7 ± 7.3 13.3 45.3
weighted  
average
91.5 ± 9.6 82.0 ± 7.5 20.1 58.2
Combined systolic and diastolic
PReView 7.3 34.4
iMPROVe 4.8 34.9
ADVANCe 5.0 36.1
iNSiST 4.0 30.8
eNOVA 3.1 33.3
BSCORe 3.0 28.7
eXCeLLeNT     1.7 25.5
weighted  
average
    4.3 32.0
Table 4 Mean change in total cardiovascular risk (TCVR) and percentage of patients with reduction in TCVR $ 1 category from 
baseline to 90 days
  Total cardiovascular risk Percent of patients with TCVR   
reduction $ 1 risk category   Min 
(↓ TCVR)
Max 
(↑ TCVR)
M ± SD
BSCORe -4 +3 -0.75 ± 0.94 60.9
eXCeLLeNT -4 +3 -0.73 ± 0.96 58.2
weighted average     -0.74 ± 0.95 59.5
Notes: Negative indicates decline in TCVR, positive indicates increase in TCVR.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 5 Percent of variance in effectiveness outcomes at 90 days 
attributable to a physician class effect
Blood pressure 
Systolic Diastolic TCVR
% % %
PReView 24 25  
iMPROVe 21 24  
ADVANCe 22 22  
iNSiST 24 23  
eNOVA 24 18  
BSCORe 21 26 13
eXCeLLeNT 22 26 16
weighted average 22 24 15
Abbreviation: TCVR, total cardiovascular risk.
Systolic blood pressure
Across the seven studies (Table 6), patient-related determi-
nants of elevated SBP (positive slope coefficient) included: 
age; SBP at the initial diagnosis of a patient’s hypertension 
and SBP at start of a valsartan-centric treatment regimen; 
risk factors such as diabetes and retinopathy (as a proxy 
of advanced diabetes), total cholesterol at baseline, and 
being a patient who fits the profile of being highly vulner-
able to uncontrolled blood pressure.35 Patients’ medication 
behavior was a consistent determinant. Nonadherence had 
a SBP-elevating effect. In contrast, patient and/or physician 
rated adherence had a SBP-lowering effect. Physicians 
who had been practicing longer tended to have patients 
with higher SBP levels at the end of 90 days. Conversely, 
seeing more hypertensive patients was associated with a 
decrease in SBP; as was using evidence-based systolic 
triggers for initiation or intensification of antihypertensive 
treatment.
Diastolic blood pressure
Patient-related variables that had a DBP-elevating effect 
included being male; DBP at initial diagnosis and at initia-
tion of valsartan treatment; obesity; fitting the profile of high 
vulnerability to uncontrolled hypertension; and longer time 
intervals between blood pressure measurements (Table 7). 
Nonadherence had a negative effect on DBP, but adherence 
a positive effect. Other DBP-lowering variables included 
age, concomitant ACE inhibitor treatment. As with SBP, 
patients seeing older physicians tended to have higher 
DBP, but physician experience in treating hypertension had 
a DBP-lowering effect. Using diastolic triggers for treat-
ment initiation or intensification, and routinely calculating 
patients’ overall cardiovascular risk were also predictive 
of lower DBP.
TCVR
The interpretation of slope coefficients for the multilevel 
models for changes in TCVR is the opposite of what applied 
to SBP and DBP. The intent was to measure improvement 
(and thus a decrease) in TCVR, with the best possible score 
being -4 and the worst score being +4. Hence a positive slope 
coefficient indicates that a given variable worsens TCVR, 
whereas a negative coefficient denotes that a variable less-
ens and thus improves the patient’s risk. TCVR worsened 
the higher the SBP at initial diagnosis and at initiation of 
valsartan treatment, and if the patient had diabetes or dys-
lipidemia (Table 8). In contrast, being female and not having 
pre-existing risk factors was associated with improvements 
in TCVR. The largest effects were observed for patients’ 
TCVR level at baseline; note the successive, consistently 
increasing negative coefficients for each level of added risk 
relative to the average risk for the population at large. Except 
for two apparent paradoxical physician-related variables, no 
physician determinants were retained.
Logistic modeling of determinants of uncontrolled blood 
pressure and achieving a TCVR reduction of at least one 
category.
SBP control
The likelihood of uncontrolled SBP (Table 9) is a function 
of such patient factors as age, SBP at the initial diagnosis of 
hypertension and at baseline, diabetes, fitting the high vulner-
ability profile, being at high added or very high added TCVR, 
smoking, hypercholesterolemia, non-adherence, and months 
elapsed since last BP measurement. Conversely, uncontrolled 
SBP was less likely if the patient was male, had controlled 
SBP at baseline (and thus was started on valsartan because 
prior line of treatment was not tolerated), no pre-existing 
conditions or risk factors, and physician-rated adherence. On 
the physician end, while years in practice was associated with 
uncontrolled SBP, control was more likely if the physician 
knew the correct BP targets for non-diabetic patients and 
practices according to the recommended SBP thresholds for 
treatment initiation and intensification.
DBP control
Uncontrolled DBP was a function of the diastolic reading when 
hypertension was diagnosed, being diabetic or obese, fitting the 
high-vulnerability profile, and being at moderate added, high 
added, or very high added TCVR at start of valsartan therapy, 
and treatment non-adherence (Table 10). Increasing age, the 
absence of pre-existing conditions and risk factors, concomi-
tant ACE inhibitor treatment, and physician-rated adherence Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 8 Multilevel modeling of change in TCVR score from baseline to 90 days
BSCORE EXCELLENT
intercept -4 to +4 0.982 1.222
Patient-related variables
  SBP at initial diagnosis of hypertension per mmHg 0.004
  SBP at baseline per mmHg 0.003
  Female gender if female -0.127
  Total cardiovascular risk: low added risk if present -0.932 -1.141
  Total cardiovascular risk: moderate added risk if present -1.644 -1.819
  Total cardiovascular risk: high added risk if present -2.215 -2.327
  Total cardiovascular risk: very high added risk if present -3.263 -3.414
  Conditions and risk factors: no pre-existing if present -0.395 -0.358
  Conditions and risk factors: diabetes if present 0.750 0.626
  Conditions and risk factors: dyslipidemia if present 0.193 0.117
  Concomitant antihypertensive treatment: ACe inhibitor if present 0.216
  Concomitant antihypertensive treatment: diuretic if present 0.109
  Physician-rated adherence per point (0–100 scale) -0.009 -0.009
Physician-related variables
    Correct response to initial antihypertensive treatment if  
1 or 2 risk factors present
if correct 0.148
    Correct blood pressure values for hypertension diagnosis  
in diabetic patients
if all correct 0.116
Abbreviations: ACe, angiotensin converting enzyme; TCVR, total cardiovascular risk; SBP, systolic blood pressure.
were predictive of controlled DBP. Whether a patient began 
valsartan treatment with controlled or uncontrolled DBP was 
associated with corresponding control status 90 days later. 
While, again, physicians’ years in practice was predictive of 
uncontrolled DBP, a high volume of hypertensive patients over 
the 12 months preceding the study, increased frequency of 
visits in the first 3 months following the diagnosis of hyperten-
sion, and practicing in accordance with evidence-based DBP 
thresholds for treatment initiation and intensification were 
predictors of controlled DBP at 90 days.
Combined SBP/DBP control
Several of the determinants of uncontrolled SBP or DBP 
also influenced the likelihood of both SBP and DBP being 
uncontrolled (Table 11). On the patient end, negative deter-
minants included: age, SBP at hypertension diagnosis and at 
baseline, diabetes, fitting the high-vulnerability profile, high 
added or very high added TCVR, prior MI, hypercholester-
olemia, and non-adherence behavior. Positive determinants 
consisted of: male gender, no pre-existing conditions or risk 
factors, and physician-rated adherence; in addition to SBP 
and DBP both under control at baseline. Physician-wise, 
years in practice was associated with uncontrolled SBP/
DBP, while having seen more hypertension patients over 
the past 12 months, knowing the BP targets for non-diabetic 
patients, and practicing in accordance with SBP thresholds 
for treatment initiation and intensification made control of 
both SBP and DBP at follow-up more likely.
TCVR reduction by at least one category
Patients were more likely to reduce their TCVR by at least 
one category if at baseline they were in the moderate added, 
high added, or very high added TCVR categories, had no pre-
existing conditions, and were perceived by their physician 
as being adherent (Table 12). Alternately, being older, male, 
diabetic, and dyslipidemic made it less likely for patients to 
reduce their TCVR by at least one category. Understandably, 
the few patients who had both SBP and DBP controlled at 
baseline were also less likely to reduce their TCVR.
Discussion
Our studies confirm that second- or later-line treatment with 
valsartan, in its different formulations, has major pharma-
cotherapeutic benefits in lowering BP and TCVR within a 
90-day time period in patients for whom prior line treatment 
failed or was not tolerated. These effects were observed with 
remarkable reliability across all seven studies – and thus 
across time, formulations, and heterogeneous populations 
of patients, physicians, and settings. Thus our program of 
research, with its conceptual, methodological, and statisti-
cal consistency, establishes the real-world effectiveness of 
valsartan-centric treatment regimens. Further, this pharma-
cotherapeutic benefit was shown to be complemented by 
modifying, managing, or taking into account patient- and 
physician-level variables that may have a negative impact 
on BP and TCVR outcomes; and optimizing those that may 
enhance these outcomes. In other words, we can conclude Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
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deductively that valsartan is indeed efficacious in the real 
world as its pharmacologic benefits were shown to prevail 
despite the large heterogeneity in patients, clinicians, and 
treatment approaches compared to RCTs.
We observed that valsartan regimens were associated 
with absolute reductions in mean SBP of -18.4 mmHg and 
mean DBP of -9.5 mmHg compared with baseline values. In 
their meta-analysis of 354 randomized trials of BP-lowering 
drugs, Law et al46 reported BP reductions associated with 
ARB treatments at the lowest available dose (eg, valsartan 
80 mg), twice the lowest available dose (eg, 160 mg), and 
in dual combination therapy. For SBP these reductions were 
-10.3 mmHg, -12.3 mmHg, and -14.6 mmHg   respectively, 
well below the weighted average of -18.4 mmHg in our 
studies. Triple combination therapy was associated with a 
reduction of   -19.9 mmHg, slightly better than the single and 
dual therapies in our studies. Likewise, in this meta-analysis 
DBP reductions associated with the lowest available dose, 
twice the lowest available dose, and dual combination therapy 
were -5.7 mmHg, -6.5 mmHg, and -7.3 mmHg,   respectively, 
compared with the weighted average of -9.5 mmHg in our 
studies. Again, triple therapy was slightly more effective 
(-10.7 mmHg).
BP control rates varied across our studies, with later 
studies trending towards lower control rates. This trend can 
be explained quite readily as a function of the regimens 
studied. Over time, our studies involved increasingly stronger 
formulations of single and combination therapies of various 
dosages of valsartan, beginning with 80 mg, 160 mg, and 
8 mg/12.5 mg HCTZ in the PREVIEW study to the full com-
plements of valsartan plus HCTZ (BSCORE) or amlodipine 
(EXCELLENT). Plausibly, our studies evolved from ‘typi-
cal’ hypertensive patients requiring second-line treatment to 
increasingly more difficult-to-treat, if not treatment-resistant, 
patients as studies progressed over time.
The observed control rates are cause for concern for 
clinicians as they may indicate persistent therapeutic inertia 
in hypertension management: not intensifying treatment 
when evidence-based targets have not been reached. On the 
other hand, the control rates in our study are not unusual 
for Europe. Using the same parameters as our studies 
(140 mmHg/90 mmHg; 130 mmHg/80 mmHg if diabetic), 
the worldwide i-SEARCH cohort study reported overall 
SBP, DBP, and combined SBP/DBP control rates of 25.2%, 
Table 12 Logistic regression of achieving a TCVR reduction (improvement) $1 category from baseline to 90 days (variables with 
significant odds ratios and 95% confidence interval not crossing 1.00)
BSCORE EXCELLENT
Patient-related variables
  Age per year 0.98
  Male gender if male 0.52
  Controlled SBP and DBP at baseline if present 0.50
  Total cardiovascular risk: moderate added risk if present 5.57 3.02
  Total cardiovascular risk: high added risk if present 11.12 3.19
  Total cardiovascular risk: very high added risk if present 104.28 48.44
  Conditions and risk factors: no pre-existing if no pre-existing 2.07 3.66
  Conditions and risk factors: diabetes if present 0.19
  Conditions and risk factors: dyslipidemia if present 0.71
  Concomitant antihypertensive treatment: alfa blocker if present (0.51)
  Concomitant antihypertensive treatment: other than alfa blocker if present (2.28)
  Physician-rated adherence per point (0–100 scale) 1.03 1.02
Physician-related variables
    Correct responses to questions related to evidence-based 
hypertension management
per response (0–4) (0.78)
Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood pressure; TCVR, total cardiovascular risk.
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42.5%, and 21.2%, respectively.47 For Northern European 
countries, which included Belgium, Germany, Sweden, and 
Switzerland, these rates were 17.5%, 35.5%, and 13.4%. 
Note that other studies have suggested different geographical 
control rates (SBP/DBP combined) for periods concurrent 
with ours, including 50.1% in the US48 and 65.9% in Canada49 
versus 27.1% in central and eastern Europe50 and 28.0% in 
England.51 This divergence may be a function of differences 
in awareness and treatment across regions, though study 
design differences may contribute just as much. As our stud-
ies employed convenience referred samples, the i-SEARCH 
study47 may be a better benchmark than a population-based 
study like NHANES in the US.48 Regardless, all control rates 
reviewed here are below the 75% hypertension control rate 
considered ‘optimal’.52
Reductions and shifts in TCVR observed in our studies were 
due to hypertension management only – possibly a criticism 
of any claims about the observed effects on TCVR.   Arguably, 
there might instead be reason for clinical optimism, albeit 
initial: adequate hypertension management in itself results in 
significantly lower residual cardiovascular risk, a finding we 
also observed in a recent study on the direct renin inhibitor 
aliskiren.13 One can only speculate what the results would be 
of conjointly managing blood pressure, glucose, lipids, obesity, 
diet, activity, smoking, and alcohol consumption in patients at 
varying levels of TCVR.12 The average decreases in the inci-
dence of stroke (35%–40%), coronary events (20%–25%), and 
congestive heart failure (50%) associated with antihypertensive 
therapy16 therefore might rise if more than one element of the 
TCVR equation is addressed clinically.
TCVR underscores the importance of patient   involvement – 
from adherence to their prescribed medication regimens to 
making the necessary life style modifications. It has been 
hypothesized that providing patients with information on 
their global coronary risk may lead to subsequent declines 
in risk. A recent systematic review of 18 studies concluded 
that such information may increase a patient’s accuracy of 
perceived risk and motivate those at moderate to high risk to 
start therapy. However, it was associated with only -0.2% to 
-2% 10-year reductions in Framingham scores, and whether 
this was a function of patient knowledge or the intensity of 
the accompanying interventions was unclear.53 If patient 
knowledge is indeed not power,54 the answer may lie in using 
this information to motivate patients into better self-care.
Multilevel and logistic modeling
Our studies were the first to quantify the physician class 
effect in antihypertensive treatment. The implications are 
significant. Mathematically, SBP could be improved by 22% 
and DBP by 24% if any physician influence were removed. 
While admittedly a theoretical exercise, the SBP weighted 
average mean reduction of -18.4 mmHg could be extended 
to -23.6 mmHg, and the corresponding DBP reduction 
of -9.5 mmHg to -12.5 mmHg. This begs the question as 
to what physician-related determinants need to be addressed 
to decrease the diversity among physicians. The multilevel 
modeling results from our studies provide important insights 
in the relationship between experience, knowledge, and 
evidence-based practice.
Paradoxical results or proxies  
for clinical vigilance?
As summarized in Table 13, some patient variables were 
associated with outcomes that seemed counterintuitive; for 
instance, presenting with more risk factors or being treated 
concomitantly with other antihypertensive agents. Similarly, 
physician variables such as greater knowledge about hyper-
tension, its management in general and in specific patient sub-
groups, identifying correct BP targets, guideline-congruent 
practice, recent continuing education in hypertension, and 
longer visits with newly diagnosed patients were statistically 
significant indicators of treatment outcome. Seemingly para-
doxical, these results all point at – hypothetically at least – the 
importance of physician attention and should be considered, 
we believe, proxies of clinical vigilance.
Modifiable, manageable, and fixed  
determinants
Table 14 presents a conceptual summary of the determinants 
of BP outcomes, BP control, TCVR change scores, and 
TCVR reduction by one or more categories. Any variable 
retained at least once in the models (Tables 9 through 12) 
are specified in terms of their influence on the effectiveness 
parameters of interest. Distinguishing between modifiable, 
manageable, and fixed determinants, we focus here on the 
clinical implications.
Patient
Modifiable patient determinants
A first key modifiable factor, presenting without pre-existing 
conditions or risk factors, does not concern changing but 
rather maintaining clinical status. This requires patient 
education and patient self-care: teaching the patient about 
predisposing conditions and risk factors, but even more 
importantly, enabling patients to prevent conditions or risks 
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life style, regular monitoring of key markers and behaviors, 
to name the most important.
At the other end of the continuum are those patients where 
primary prevention failed and who fit the ‘lazier, later, and 
unluckier’ profile of being highly vulnerable to uncontrolled 
hypertension following treatment with a   valsartan regimen 
(at least per the PREVIEW study).19,35 This profile has not 
yet been shown to directly impact TCVR outcomes. It can 
be assumed to do so as it is an independent predictor of 
BP   control35 and thus may have an effect on TCVR as a 
  BP-linked indicator. These findings reaffirm the importance 
of patient self-care behavior, in particular treatment adher-
ence and lifestyle modifications. As to the latter, our studies 
confirm that patients should not smoke; eat a low fat, car-
bohydrate balanced, and low sodium diet; lose weight; and 
implicitly (under the calculation of TCVR status) exercise 
condition- and age-appropriately. These lifestyle modifi-
cations will also benefit patients with   dyslipidemia who, 
moreover, should be treated with lipid-lowering agents. 
Lifestyle-related (as opposed to metabolic) obesity is a 
modifiable variable as well.
Patients in our studies were in at least the second line 
of antihypertensive treatment, mainly because of failure of 
prior line treatment to achieve BP control. Many fell in the 
difficult-to-treat if not treatment-resistant categories. As 
BP control most often requires combination therapy, our 
modeling results indicate that concomitant ACE inhibitor 
therapy is effective, and certainly is indicated in patients with 
diabetes (for whom this is considered the standard of care). 
Note that all other classes of antihypertensive agents (prior to 
direct renin inhibitors) also emerged in the models – though 
in a paradoxical direction as a proxy of clinician vigilance. 
This underscores the importance of adjunct anti-hypertensive 
therapy to complement valsartan treatment.
TCVR is an eminently modifiable determinant. As the 
BSCORE40 and EXCELLENT41 studies showed for valsartan, 
but also more recently the DRIVER13 study for aliskiren, 
TCVR can be reduced significantly through antihypertensive 
treatment. This breaks the vicious circle of hypertension 
and elevated TCVR, and adds preventive cardiovascular 
as well as renoprotective effects. The TCVR findings also 
reveal a direct relationship between severity of TCVR and 
the likelihood of achieving a reduction in TCVR following 
valsartan (or aliskiren) treatment: the more room there is for 
improvement, the greater the likelihood – logically so.
A final modifiable factor that may enhance valsartan 
treatment outcomes concerns BP monitoring. Shorter time 
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better treatment outcomes, most likely because this enables 
clinicians to intensify treatment sooner – reducing therapeutic 
inertia along the way. Patients may further benefit if they 
also perform home BP monitoring. A recent meta-analysis 
concluded that, compared with office monitoring alone, 
home monitoring added small but significant reductions in 
SBP and DBP, led to more frequent antihypertensive medi-
cation reductions, and was associated with less therapeutic 
inertia.55
Manageable patient determinants
SBP and DBP levels at the initial diagnosis of hyperten-
sion, as well as SBP and DBP levels at the start of valsartan 
therapy, were associated with better BP and TCVR outcomes, 
which underscores the importance of early diagnosis and 
early intervention. The sooner high blood pressure is diag-
nosed (or, perhaps better, when patients move from normo-
tensive or pre-hypertensive into grade I hypertension), the 
more likely it is that SBP and DBP will decrease, SBP and 
DBP will be controlled, TCVR will improve, and a TCVR 
reduction of at least one category will be achieved over 
90 days of valsartan treatment.
Early diagnosis and early initiation of valsartan treatment 
had a singular effect on SBP reduction and SBP control, 
suggesting the effectiveness of valsartan in lowering iso-
lated systolic hypertension. There was also an association of 
DBP at diagnosis and valsartan start with subsequent DBP 
reduction and control. This may reflect in part the historical 
practice of focusing on DBP in hypertension diagnosis and 
management.
BP reduction and control are more difficult to achieve in 
diabetic patients. This challenge was found in our studies as 
well (data not reported but available from the corresponding 
author), especially in patients with advanced diabetes (as 
evidenced, for instance, by retinopathy). Further, patients with 
diabetes fall by definition into a higher TCVR category and 
reductions in TCVR may be more difficult to achieve. Hence 
diabetes needs to be managed aggressively to improve BP 
outcomes and TCVR, to prevent (hypertension-compounded) 
chronic kidney disease, to manage the hypertension– 
diabetes–dyslipidemia–renal disease axis, and to optimize 
the outcomes of antihypertensive treatment in general and 
with valsartan in particular.
Patients with a prior MI are less likely to achieve BP 
control, in addition to having an increased TCVR a priori. To 
promote general cardiovascular health, prevent an MI recur-
rence, and reduce MI-associated cardiovascular morbidity, 
hypertension control is essential. As valsartan is among the 
most potent antihypertensive agents, it should be among the 
treatments of choice for patients with a history of MI.
Fixed patient determinants
Our studies confirm prior evidence that advanced age nega-
tively affects SBP, but positively affects DBP when considered 
separately (compromises achieving combined SBP/DBP con-
trol). Advanced age increases the likelihood of reducing TCVR 
by at least one catgeory.23,48,56–59 In a subanalysis of patients age 
65 and older in the PREVIEW study, control rates were lower 
yet modeling identified factors similar to those in the study at 
large.60 Importantly, the percentages of variation in BP values 
attributable to a physician class effect were higher: 27% for SBP 
(versus 24% in PREVIEW and 22% in this present analysis) 
and 32% for DBP (versus 27% and 24%, respectively). This 
underscores the importance of physicians treating older adults 
within the guidelines for this subpopulation.
Further, for each increase in age by 10 years, the likeli-
hood of controlled BP decreases by 10% for men and 20% 
for women.61 Across our studies, men were more likely to 
achieve SBP and SBP/DBP control, as well as TCVR reduc-
tion by one or more categories; whereas women showed 
greater improvements in TCVR score. In another subanalysis 
of PREVIEW, fewer women than men reached SBP and SBP/
DBP control. The multilevel and logistic models showed 
that men who lacked regular exercise or were non-adherent, 
were more vulnerable to uncontrolled SBP, whereas women 
were more vulnerable to uncontrolled BP because of identifi-
able physician-level variables such as the number of hyper-
tensive patients seen in the past 12 months and the number 
of follow-up visits to achieve BP control.62
Understandably, controlled BP at baseline, when valsartan 
treatment was initiated, was predictive of BP control at 
90 days. Each study enrolled small proportions of patients 
with controlled BP who did not tolerate their prior antihy-
pertensive treatment. It can be assumed that these patients 
tended to have less severe hypertension and/or be good 
responders and/or be good adherers. Yet the importance of 
this finding is that BP control can be sustained successfully 
with valsartan treatment.
Physician
Modifiable physician determinants
Our studies revealed several physician-related variables that 
are modifiable through both medical education and self-
initiated physician change. Knowledge about evidence-based 
hypertension management is critical. Knowing BP targets 
for patients in general, and specific subgroups such diabetic, Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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elderly, or high risk patients, is associated with better treat-
ment outcomes. Limited knowledge impairs physicians’ 
ability to treat more complex patients such as the difficult-
to-treat or the treatment-resistant. On the other hand, one 
cannot expect general practitioners to be able to manage all 
patients and to be ‘pseudo hypertension specialists’. Hence 
the need for regular interaction with specialists, and timely 
referral of poorly responding or highly complex patients to 
these specialists for consultation.
While clinical knowledge does not assure clinical behavior 
change, our studies consistently point at the importance of 
practicing in accordance with evidence-based guidelines for 
treatment initiation and intensification, ie, knowing when and 
how to start and when and how to escalate antihypertensive 
treatment (in this case, with valsartan). This will avoid 
delayed pharmacological intervention, and reduce therapeutic 
inertia when patient response is below target. In the process, 
regular monitoring of patients especially in the first 3 months 
after diagnosis and treatment initiation, and routinely calcu-
lating patients’ total cardiovascular risk, is associated with 
better patient outcomes. Assuming our proxy hypothesis is 
plausible, diagnostic and therapeutic physician vigilance is 
critical in preventing adverse treatment outcomes.
Our studies identified a relationship between (self-
reported) guideline-congruent practice and BP outcomes. 
Important in itself, this finding does not answer the more 
critical question of whether individualized, evidence-based 
care at the individual patient level translates into lower and 
controlled BP. Evidence-based medicine may be forgetting to 
focus on evidence-based individualized patient care decision-
making.63 However, a quantification of the extent to which 
the care of each individual patient increases the likelihood of 
treatment response has been shown to increase the likelihood 
of positive treatment outcomes by a factor of almost 3 in the 
management of chemotherapy-induced anemia in cancer 
patients.64 Future studies in hypertension should benefit from 
a similar assessment.
Manageable and fixed physician determinants
Physician experience may be a double-edged sword in 
hypertension management in primary care. The number 
of hypertensive patients in the twelve months preceding 
start of a study was associated with better BP values and 
better control rates after 90 days of valsartan treatment. 
Logically, experience by volume should indeed translate 
into better outcomes, perhaps in part because clinicians’ 
treatment patterns become more consistent across patients. 
Yet by being generalists, primary care physicians cannot 
be expected to ‘subspecialize’ in particular diseases at the 
expense of their public trust function to serve patients in their 
communities. What could be expected realistically is that they 
regularly appraise their confidence in, and the outcomes of, 
antihypertensive treatment in their patients – and be provided 
with support to do so. One indeed learns from (safe) self-
experimentation and self-observation. It is not uncommon for 
clinicians to engage in exercises in which they (often unsys-
tematically) observe their practice behavior and try to infer 
treatment effectiveness from (most often unsystematically 
collected) data. They should be supported to ‘micro-trial’ to 
garner ‘micro-evidence’, and thus gain clinical confidence 
and change clinical practice behavior.65
In contrast to the positive effect of experience by patient 
volume stands the negative association of experience in years 
with BP outcomes. The longer the time since physicians had 
graduated from medical school and had been in practice, the 
greater the likelihood of poorer BP outcomes. One cannot 
assume this to be a linear relationship. This would mean that 
patients treated by junior physicians would have the best 
outcomes – an argument that can be negated without the 
need for scientific evidence. Rather, the relationship might 
be concave, where physicians’ treatment outcomes improve 
in the early career years, peak over some period of time, only 
to decline later on.30
Real-world effectiveness of valsartan
Valsartan’s real-world effectiveness was demonstrated 
consistently across the continuum of treatment response, 
with particularly encouraging results in difficult-to-treat if 
not treatment-resistant patients. The latter is important as, 
until the approval of aliskiren, valsartan quadruple lowest 
available dose (320 mg) as well as lowest available dose 
(80 mg) and double lowest available dose (160 mg) single-
pill combinations with HCTZ 25 mg or with 5 mg or 10 mg 
amlodipine (Table 2) were the most potent antihypertensive 
agents available. Blood pressure control remains a moving 
target; there is more uncontrolled disease despite improved 
therapy,16 and aliskiren and aliskiren/HCTZ have become the 
antihypertensive treatment of (the proverbial) last resort. This 
means that valsartan-based regimens should be the prevail-
ing if not standard model to manage patients ranging from 
those with (modest) hypertension not controlled by prior line 
therapy to those persistently failing to respond to escalating 
combination therapies and intensifying dosing schemes.
Critically, and despite its pharmacological benefits, 
valsartan’s real-world effectiveness is amplified signifi-
cantly through parallel preventive and interventive actions. Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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These should involve patients in general but especially target 
those with elevated risk for non-response or secondary cardio-
vascular, renal, or other organ or physiological damage. Just 
as critically, this should occur within a context of enabling 
physicians to gain in knowledge and experience and to prac-
tice in accordance with evidence-based guidelines. Lastly, 
while we did not report such data from our studies in this 
article, the positive safety and tolerance profile of valsartan 
should be considered in clinical decision-making as well.
More generally, using valsartan as the exemplar, our 
findings confirm and extend an earlier proposed three-step 
approach to optimizing the real-world effectiveness of anti-
hypertensive treatment.19 First, clinicians should identify 
patients less likely to achieve BP control. Deterministic 
models may ensure the greatest accuracy, however heuristic, 
clinically more intuitive, yet empirically validated methods 
may prove easiest to use in routine primary care practice.35 
Within the (time) confines of a clinical encounter, it may be 
better to get a sense of risk and empathetically communicate 
this concern to the patient. This might indeed be more effec-
tive than calculating the actual percentage of increased risk 
for an adverse cardiovascular event and citing that statistic 
to the patient during a clinical encounter. Most likely, the 
patient will have difficulty placing this statistic within a fair 
probabilistic context.66
Nonetheless, to support their own clinical decision-making, 
clinicians should routinely assess patients’ TCVR and, per 
guidelines,9,10 grade antihypertensive therapy accordingly. 
In the absence of heuristic methods, deterministic models 
are indicated. While they may take more time, the pay-off 
for anyone with added cardiovascular risk is warranted from 
clinical, quality of life, and cost perspectives. Second, at the 
risk of repetition, clinicians and patients should focus on 
modifiable and manageable patient- and physician-related 
determinants known to affect BP values and TCVR scores 
positively or negatively (while being cognizant of the fixed). 
Lastly, the goal should be to lower the odds of uncontrolled 
BP and the odds of not achieving reductions in TCVR.
Patient adherence
Patients indeed have a significant self-care responsibility in 
the management of their hypertension and the prevention 
of target organ damage and major cardiovascular events. 
A meta-analysis documented that the likelihood of a poor 
or null response to antihypertensive treatment is reduced by 
30% but that the odds of responding to treatment are 3.44 if 
patients are adherent.67 Osterberg and Blaschke68 summarize 
strategies to improve medication adherence in general and 
these strategies apply to hypertension as well: identifying 
the potential for or patterns of non-adherence; focusing 
on the patient by eliciting feelings, listening, reinforcing 
desirable behaviors, and customizing treatment to patient 
wishes; patient education through explanation and clear 
instructions; engaging the patient’s family, social, and com-
munity environment; encouraging the use of medication-
taking systems; and altering treatment to more ‘forgiving’ 
medications. In hypertension, the large number of studies 
about non-adherence is by far not matched by (non) con-
trolled studies on effective interventions. Hence, general 
suggestions67 are helpful but largely untested suggestions 
that are unlikely to reduce the persistent problem of patient 
non-adherence.
One new insight from our research program is that 
intuitive physician assessment may have a positive effect – 
certainly on BP and TCVR outcomes.   Physician-rated adher-
ence using a visual analog scale was predictive of lower 
SBP and DBP; SBP, DBP, and SBP/DBP control; change 
in TCVR; and achieving a TCVR reduction of at least one 
category. This finding may not indicate an improvement in 
patient adherence, but it underscores two critical elements. 
First, knowing that patient self-reports are seldom accurate, 
physicians in our studies may have chosen to go by their 
own hic et nunc assessment – with clinical functionality 
to assess a potential problem quickly and without needing 
validation. Second, they may have adapted their clinical 
approach if they sensed manifest (or risk for) non-adherence 
behavior. Sensing may have been the clinical trigger, not 
whether their visual analog scale rating was congruent 
with actual patient behavior (most likely, it wasn’t). It may 
have led them to implement some or all of the suggestions 
offered by Osterberg and Blaschke,68 but most likely clinical 
experience taught them to be helpful. Hypothetically, patient 
adherence may be the conjoint result of clinician alertness 
and sensitivity, integration of assessment and immediate 
intervention in the clinical encounter, and the sensitization 
and (partial) responsiveness of the patient.
Class effects on treatment outcomes
Clinicians do indeed exert a class effect over the patients they 
treat (and contribute to studies). We already discussed above 
the specific findings from our valsartan findings. The implica-
tions are broader. Clinicians need to be aware that how they 
assess, diagnose, and treat their patients has a class effect: a 
core similarity that transcends patients, may very well con-
stitute the primary driver of their approach to hypertension 
management, and is tied to their education, training, exposure, Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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and experience. More generally, any claims of individualized 
treatment tailored to each patient separately should be taken 
with some scepticism. Patterns of care are a reality – and not 
necessarily negatively so. Our studies only demonstrate a) 
that a significant amount in outcome variability is attributable 
to clinicians, and b) that some positive and negative drivers 
can be identified through modeling.
It is useful here to speculate about class effects beyond 
individual clinicians. Though typical for the Belgian primary 
care system, most physicians in our studies were in solo 
practice, and being part of a group or hospital-based prac-
tice may add another layer of class effect. For instance, we 
have found that hemoglobin outcomes in the management of 
anemia secondary to antineoplastic treatment are a function 
of center, country, and (European) region where the patient 
was treated.69
Scientific issues
Replication
RCTs tend to be replicated in ways that closely resemble 
the methodological and statistical platforms of the reference 
study – the goal being confirmation of initial (statistically 
powered) findings. Methodological and statistical similarity is 
seldom true in observational studies. In the case of valsartan, 
it explains the pervasive heterogeneity of studies and the 
quasi impossibility of synthesizing these studies in ways that 
consider differences in approach. The merit of our research 
program of seven valsartan-focused studies is that, despite 
some minor occasional differences between studies, these 
investigations were virtually identical in approach. Where 
differences in results were observed, these could be explained 
with appropriate certainty as a function of treatment regimen 
or sample. Findings that were consistent across studies can 
be assumed to be robust.
Observational studies, treatment effects, 
and causality
Our studies also underscore the importance of observational 
studies in determining the real-world effectiveness of treat-
ment regimens. Poorly designed observational studies 
may under- or overestimate treatment effects. Yet there is 
strong empirical evidence that well-designed pharmaco-
  epidemiologic observational studies provide not only accurate 
estimates of treatment effectiveness, but also broaden the 
understanding of the clinical dynamics of treatment, clinician, 
patient, and environment.70,71
Many physicians continue to hold the (erroneous) belief 
that only RCTs permit inferences of causality – even when 
they would not challenge the Surgeon General’s Report on 
the health effects of smoking72 (associative evidence) or 
would not advocate a randomized trial of adequate versus 
inadequate hemodialysis when the latter has clearly been 
linked to mortality73 (associative evidence rendering RCTs 
unethical). The social and behavioral sciences have developed 
methodologies and statistical approaches to analyse non-
experimental data to enable decisions from individual people 
all the way up to populations and societies. The relevance 
and appropriateness of these findings for clinical research 
has been demonstrated for a long time,74 yet resistance to 
these principles and methods remains – discouragingly and 
scientifically indefensibly so.
To what extent do our studies provide evidence that 
valsartan is the cause of reductions in BP and TCVR – in 
interaction with and as a function of the many determinants 
that have been identified? Mosteller75 identifies four   criteria: 
1) consistency or that the same effects are achieved regularly, 
and across people and time; 2) responsiveness, ie, evidence 
that variations in treatment precede variations in effects; 
3) a mechanism that explains how the effect is created; 
and, citing Lipsey,76 4) uniqueness, or the ability to dismiss 
alternative explanation of the effect other than the treatment. 
Recently, Harrell argued that causal inferences from observa-
tional data can be trusted if 1) the prognostic factors are well 
understood and were collected; 2) the data are rich, accurate, 
and collected purposively; 3) treatment by indication is well 
understood/characterized; 4) the research is reproducible; 
5) statistical analysis is appropriate; and based on 6) a pre-
specified analytic plan.77 The studies in our research program 
meet both the Mosteller and Harrell sets of criteria.
TCVR as an effectiveness indicator
The TCVR classification used in the BSCORE and 
  EXCELLENT studies comprised five levels: average risk, 
low added risk, moderate added risk, high added risk, and 
very high added risk. Conceivably, the five levels might be 
too limited to sensitively and accurately quantify TCVR; as 
might be the nine levels of change in TCVR (-4 to +4). The 
fact that in both studies, as well as a recent study on aliskiren,13 
this method differentiated sufficiently among patients to be 
retained in modeling emphasizes the appropriateness and 
relevance of TCVR as an effectiveness indicator. As noted, 
future studies should incorporate other elements of TCVR.
Conclusion
This paper described a unique translational research program 
of seven studies on the real-world effectiveness of valsartan, Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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among the most widely prescribed antihypertensive agents. 
In its different formulations, valsartan has major ‘real-world’ 
pharmacotherapeutic benefits in lowering BP and TCVR 
within a 90-day time period in patients in whom prior line 
treatment failed or was not tolerated. It is essential to under-
stand the patient- and physician-related determinants of BP 
and TCVR outcomes associated with valsartan treatment. The 
evidence from our translational research program is robust: the 
findings are persistent across time, formulations, patients, and 
clinicians. Importantly, clinicians and patients need to be aware 
of the many treatment-, clinician-, and patient-related variables 
that may ‘cause’ variations in BP and TCVR outcomes. Many 
of these variables are modifiable and manageable through care-
ful intervention and responsive patient self-care behavior.
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